Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial

Muscle and Nerve

Volumn 53, Issue 3, 2016, Pages 363-369

  Benatar, Michael ^a,b   McDermott, Michael P ^a,c   Sanders, Donald B ^a   Wolfe, Gil I ^a,j   Barohn, Richard J ^a,e   Nowak, Richard J ^a,g   Hehir, Michael ^a,f   Juel, Vern C ^a,l   Katzberg, Hans ^a,h   Tawil, Rabi ^a,c   Waltz, Alexandre ^b   Michon, Sara Claude ^b   Smirnow, Alexis ^c   Hussain, Farheen ^c   Smith, Patricia C ^c   Dilek, Nuran ^c   Janciuras, Joanne ^c   Kamp, Cornelia ^d   Hackett, Tim ^d   Bolger, Pat ^d   Woodcook, Joan ^d   McVey, April L ^e   Dimachkie, Mazen M ^e   Pasnoor, Mamatha ^e   Whittaker, Thomas J ^e   Herbelin, Laura ^e   Rico, Gabrielle ^e   Waheed, Waqar ^f   Lucy, Shannon ^f   Dicapua, Daniel B ^g   Goldstein, Jonathan M ^g   Keung, Benison ^g   Nye, Joan ^g   Bril, Vera ^h   Tapia, Carolina Barnett ^h   Breiner, Ari ^h   Kokokyi, Seint ^h   Burns, Ted ⁱ   Solorzano, Guillermo ⁱ   Joshi, Amruta ⁱ   Silvestri, Nicholas J ^j   Patrick, Kara ^j   Muppidi, Srikanth ^k   Nations, Sharon ^k   Hopkins, Steve ^k   Guptill, Jeffrey T ^l   Hobson, Lisa D ^l   Massey, Janice M ^l   Beck, Katherine ^l   more..

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d Clinical Material Services Unit (CMSU)   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f UNIVERSITY OF VERMONT   (United States)

^g YALE UNIVERSITY   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ UNIVERSITY OF VIRGINIA   (United States)

^j UNIVERSITY AT BUFFALO   (United States)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Clinical trial; Neuromuscular; Ocular myasthenia; Prednisone; Steroids

Indexed keywords

PLACEBO; PREDNISONE; PYRIDOSTIGMINE; CHOLINESTERASE INHIBITOR;

ADULT; AGITATION; ANXIETY; ARTICLE; BLEPHAROSPASM; BLURRED VISION; BRONCHITIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPHAGIA; EDEMA; FASCICULATION; FEMALE; FLATULENCE; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PALPITATION; HEMATOMA; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; MALE; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; OCULAR MYASTHENIA GRAVIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUS TACHYCARDIA; WEIGHT GAIN; AGED; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PYRIDOSTIGMINE BROMIDE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84956939177     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24769     Document Type: Article

References (31)

1. Ferguson FR, Hutchinson EC, Liversedge LA. Myasthenia gravis; results of medical management. Lancet 1955;269:636-639.
2. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-149.
3. Sanders D. Approach to diseases of the neuromuscular junction. In: Tawil R, Venance S, editors. Neuromuscular disorders. New York: Wiley; 2011. p 113-117.
4. Aiello I, Pastorino M, Sotgiu S, Pirastru MI, Sau GF, Sanna G, et al. Epidemiology of myasthenia gravis in northwestern Sardinia. Neuroepidemiology 1997;16:199-206.
5. Benatar M, Kaminski H. Medical and surgical treatments for ocular myasthenia. Cochrane Database Syst Rev 2012;12:CD005081.
6. Bever CT, Aquino AV, Penn A, S, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol 1983;14:516-519.
7. Casetta I, Fallica E, Govoni V, Azzini C, Tola M, Granieri E. Incidence of myasthenia gravis in the province of Ferrara: a community-based study. Neuroepidemiology 2004;23:281-284.
8. Lavrnić D, Jarebinski M, Rakocevic-Stojanovic V, Stevic Z, Lavrnić S, Pavlović S, et al. Epidemiological and clinical characteristics of myasthenia gravis in Belgrade, Yugoslavia (1983-1992). Acta Neurol Scand 1999;100:168-174.
9. Mount F. Corticotropin in treatment of ocular myasthenia-a controlled clinical trial. Arch Neurol 1964;11:114-124.
10. Phillips LH, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology 1992;42:1888-1893.
11. Robertson N, Deans J, Compston D. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry 1998;65:492-496.
12. Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. Incidence of myasthenia gravis in the Emilia-Romagna region: a prospective multicenter study. Neurology 1998;51:255-258.
13. Brenner T, Hamra-Amitay Y, Evron T, Boneva N, Seidman S, Soreq H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J 2003;17:214-222.
14. Benatar M, Kaminski HJ. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007;68:2144-2149.
15. Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003;60:243-248.
16. Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 2003;23:251-255.
17. Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 2004;217:131-133.
18. Papapetropoulos TH, Ellul J, Tsibri E. Development of generalized myasthenia gravis in patients with ocular myasthenia gravis. Arch Neurol 2003;60:1491-1492.
19. Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, et al. Ocular myasthenia gravis: response to long-term immunosuppressant treatment. J Neurol Neurosurg Psychiatry 1997;62:156-162.
20. Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 2008;71:1335-1341.
21. Mittal MK, Barohn RJ, Pasnoor M, McVey A, Herbelin L, Whittaker T, et al. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response. J Clin Neuromuscul Disord 2011;13:46-52.
22. Agius M. Treatment of ocular myasthenia with corticosteroids: yes. Arch Neurol 2000;57:750-751.
23. Hachinski V. Treatment of ocular myasthenia. Arch Neurol 2000;57:753.
24. Kaminski H, Daroff R. Treatment of ocular myasthenia: steroids only when compelled. Arch Neurol 2000;57:752-753.
25. Benatar M, Sanders D, Wolfe G, McDermott M, Tawil R. Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPTIOME) trial. Ann NY Acad Sci 2012;1275:17-22.
26. Jaretzki A, Barohn R, Ernstoff R, Kaminsky HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
27. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann NY Acad Sci 2003;998:440-444.
28. Mangione CM. Version 2000. The National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25). Available at: http://www.nei.nih.gov/resources/visionfunction/manual_cm2000.pdf/. Accessed December 25, 2008.
29. Raphael BA, Galetta KM, Jacobs DA, Markowitz CE, Liu GT, Nano-Shiavi ML, et al. Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol 2006;142:1026-1035.
30. Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve 2011;43:14-18.
31. Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill GT, Baggi F, et al. Recommendations for myasthenia gravis clinical trials. Muscle Nerve 2012;45:909-917.